230 related articles for article (PubMed ID: 12927041)
1. First-cycle absolute neutrophil count can be used to improve chemotherapy-dose delivery and reduce the risk of febrile neutropenia in patients receiving adjuvant therapy: a validation study.
Rivera E; Haim Erder M; Fridman M; Frye D; Hortobagyi GN
Breast Cancer Res; 2003; 5(5):R114-20. PubMed ID: 12927041
[TBL] [Abstract][Full Text] [Related]
2. Targeted filgrastim support in patients with early-stage breast carcinoma: toward the implementation of a risk model.
Rivera E; Erder MH; Moore TD; Shiftan TL; Knight CA; Fridman M; Brannan C; Danel-Moore L; Hortobagyi GN;
Cancer; 2003 Jul; 98(2):222-8. PubMed ID: 12872339
[TBL] [Abstract][Full Text] [Related]
3. Identifying patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin: the development of a prediction model.
Dranitsaris G; Rayson D; Vincent M; Chang J; Gelmon K; Sandor D; Reardon G
Am J Clin Oncol; 2008 Aug; 31(4):369-74. PubMed ID: 18845996
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy of once-per-cycle administration pegylated recombinant human granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in a phase I trial].
Yang S; Shi YK; Liu P; Han XH; He XH; Cai YM; Chen ZM
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun; 28(3):339-44. PubMed ID: 16900629
[TBL] [Abstract][Full Text] [Related]
5. Chemoprophylaxis with oral ciprofloxacin in ovarian cancer patients receiving taxol.
Carlson JW; Fowler JM; Saltzman AK; Carter JR; Chen MD; Mitchell SK; Dunn D; Carson LF; Adcock LL; Twiggs LB
Gynecol Oncol; 1994 Dec; 55(3 Pt 1):415-20. PubMed ID: 7530677
[TBL] [Abstract][Full Text] [Related]
6. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma.
Lyman GH; Delgado DJ
Cancer; 2003 Dec; 98(11):2402-9. PubMed ID: 14635075
[TBL] [Abstract][Full Text] [Related]
7. Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide.
Papaldo P; Lopez M; Marolla P; Cortesi E; Antimi M; Terzoli E; Vici P; Barone C; Ferretti G; Di Cosimo S; Carlini P; Nisticò C; Conti F; Di Lauro L; Botti C; Di Filippo F; Fabi A; Giannarelli D; Calabresi F
J Clin Oncol; 2005 Oct; 23(28):6908-18. PubMed ID: 16129844
[TBL] [Abstract][Full Text] [Related]
8. Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer.
Laskey RA; Poniewierski MS; Lopez MA; Hanna RK; Secord AA; Gehrig PA; Lyman GH; Havrilesky LJ
Gynecol Oncol; 2012 Jun; 125(3):625-30. PubMed ID: 22426251
[TBL] [Abstract][Full Text] [Related]
9. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.
Crawford J; Ozer H; Stoller R; Johnson D; Lyman G; Tabbara I; Kris M; Grous J; Picozzi V; Rausch G
N Engl J Med; 1991 Jul; 325(3):164-70. PubMed ID: 1711156
[TBL] [Abstract][Full Text] [Related]
10. First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy.
Silber JH; Fridman M; DiPaola RS; Erder MH; Pauly MV; Fox KR
J Clin Oncol; 1998 Jul; 16(7):2392-400. PubMed ID: 9667256
[TBL] [Abstract][Full Text] [Related]
11. Community-based trial of R-CHOP and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients.
Case DC; Desch CE; Kalman LA; Vongkovit P; Mena RR; Fridman M; Allen B
Clin Lymphoma Myeloma; 2007 Mar; 7(5):354-60. PubMed ID: 17562245
[TBL] [Abstract][Full Text] [Related]
12. A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer.
Siena S; Piccart MJ; Holmes FA; Glaspy J; Hackett J; Renwick JJ
Oncol Rep; 2003; 10(3):715-24. PubMed ID: 12684649
[TBL] [Abstract][Full Text] [Related]
13. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices.
Lyman GH; Dale DC; Crawford J
J Clin Oncol; 2003 Dec; 21(24):4524-31. PubMed ID: 14673039
[TBL] [Abstract][Full Text] [Related]
14. Dose-finding study of paclitaxel and cyclophosphamide in patients with advanced breast cancer.
Sessa C; Pagani O; Parma G; Goldhirsch A; Cavalli F
Semin Oncol; 1995 Jun; 22(3 Suppl 6):112-7. PubMed ID: 7541152
[TBL] [Abstract][Full Text] [Related]
15. Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity.
Ribas A; Albanell J; Bellmunt J; Solé-Calvo LA; Bermejo B; Gallardo E; Vidal R; Vera R; Eres N; Carulla J; Baselga J
J Clin Oncol; 1996 May; 14(5):1573-80. PubMed ID: 8622074
[TBL] [Abstract][Full Text] [Related]
16. A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel.
Gladkov O; Moiseyenko V; Bondarenko IN; Shparyk Y; Barash S; Adar L; Avisar N
Oncologist; 2016 Jan; 21(1):7-15. PubMed ID: 26668251
[TBL] [Abstract][Full Text] [Related]
17. Neutropenic complications in advanced-stage non-Hodgkin's lymphoma: implications for the use of prophylactic recombinant human granulocyte-colony stimulating factor (G-CSF).
Bobey N; Woodman RC
Clin Invest Med; 1998 Apr; 21(2):63-70. PubMed ID: 9562926
[TBL] [Abstract][Full Text] [Related]
18. Impact of neutropenia on delivering planned chemotherapy for solid tumours.
Khan S; Dhadda A; Fyfe D; Sundar S
Eur J Cancer Care (Engl); 2008 Jan; 17(1):19-25. PubMed ID: 18181887
[TBL] [Abstract][Full Text] [Related]
19. Implementing an evidence-based risk assessment tool to predict chemotherapy-induced neutropenia in women with breast cancer.
Chang LL; Schneider SM; Chiang SC; Horng CF
Cancer Nurs; 2013; 36(3):198-205. PubMed ID: 23051869
[TBL] [Abstract][Full Text] [Related]
20. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial.
Ravaud A; Chevreau C; Cany L; Houyau P; Dohollou N; Roché H; Soubeyran P; Bonichon F; Mihura J; Eghbali H; Tabah I; Bui BN
J Clin Oncol; 1998 Sep; 16(9):2930-6. PubMed ID: 9738560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
